LeadArtis S.L. announced the generation of multivalent and multispecific trimerbodies. By fusing single-chain variable fragments(scFv) with the same or different specificity to both N- and C-terminus of the trimerizing scaffold domain, monospecific or bispecific hexavalent molecules were successfully produced and secreted as soluble proteins by transfected mammalian cells.

LeadArtis S.L. announced that published proof-of-concept data with a new Trimerbody® molecule. Trimerbody® molecules based in human collagen XV exhibited excellent antigen binding capacity, and demonstrated greater thermal and serum stability and resistance to protease digestion than conventional type XVIII Trimerbody® molecules.

This past 3 November, the Medical Association of Barcelona (COMB) hosted the fifth edition of the Healthcare Investment Forum, a conference which aims to make private funding more accessible to companies in the healthcare sector that are in the growth phase and require an injection of up to 3 million euros of capital. Leadartis was one of the 11 companies selected, from more than 30 candidates, to present the project to more than 100 venture investors.

Click here for more information